Literature DB >> 11588061

Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.

A Y Leung1, H C Chow, Y L Kwong, A K Lie, A T Fung, W H Chow, A S Yip, R Liang.   

Abstract

CYP2C9 polymorphisms reported in Caucasians (Arg144Cys in exon 3 and Ile359Leu in exon 7) are extremely uncommon in Chinese persons. The genotype of CYP2C9 in this population was characterized to investigate its relation with the interindividual variation in warfarin dosages. Eighty-nine Chinese patients receiving warfarin were recruited. Target sequences in CYP2C9 in exons 1, 4, and 5 were amplified by polymerase chain reaction, followed by direct sequencing. Polymorphisms at 4 positions were demonstrated in exon 4. Heterozygosities for 608TTG>GTG (Leu208Val), 561CAG>CCG (Gln192Pro), 537CAT>CCT (His184Pro), and 527ATT>CTT (Ile181Leu) existed at frequencies 0.75, 0.20, 0.10, and 0.09, respectively. Seventeen patients (frequency, 0.19) were homozygous for Val208. The common genotypic combinations at these loci are Ile181/His184/Gln192/Leu208Val (n = 50), Ile181/His184/Gln192/Val208 (n = 15), Ile181/His184/Gln192/Leu208 (n = 4), Ile181/His184/Gln192Pro/Leu208Val (n = 6), Ile181/His184Pro/Gln192Pro/Leu208Val (n = 4), and Ile181Leu/His184/Gln192Pro/ Leu208Val (n = 4). At codon 208, heterozygous Leu208Val and homozygous Val208 appeared to have a lower warfarin dose requirement than the homozygous Leu208. Patients who are heterozygous for Ile181Leu had a higher warfarin dose requirement than the homozygous Ile181. Amplified sequences in exons 1 and 5 did not exhibit polymorphism. In conclusion, Chinese patients showed genetic polymorphisms of CYP2C9 in exon 4 and at codon 208; most were heterozygous Leu208Val and homozygous Val208. Homozygous Leu208, a common allele in Caucasians, is uncommon in this cohort. The significance of these CYP2C9 polymorphic alleles remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588061     DOI: 10.1182/blood.v98.8.2584

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance dose.

Authors:  Gin Gin Gan; Maude Elvira Phipps; Chee Seng Ku; Alan Teh; Vijaya Sangkar
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

2.  A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Authors:  Su-Jun Lee; Yin Jin Jang; Eun-Young Cha; Ho-Sook Kim; Sang Seop Lee; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

3.  Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients.

Authors:  Vivian W Y Lee; Joyce H S You; Kenneth K C Lee; T S Chau; Mary M Y Waye; Gregory Cheng
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

4.  A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.

Authors:  Michael A Hillman; Russell A Wilke; Steven H Yale; Humberto J Vidaillet; Michael D Caldwell; Ingrid Glurich; Richard L Berg; John Schmelzer; James K Burmester
Journal:  Clin Med Res       Date:  2005-08

5.  Novel anticoagulants in atrial fibrillation stroke prevention.

Authors:  Nicholas B Norgard; James J Dinicolantonio; Taylor J Topping; Benjamin Wee
Journal:  Ther Adv Chronic Dis       Date:  2012-05       Impact factor: 5.091

Review 6.  Polymorphism induced sensitivity to warfarin: a review of the literature.

Authors:  Michael P Palkimas; Hillary M Skinner; Pritesh J Gandhi; Alice J Gardner
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 7.  Antiplatelet medications and evolving antithrombotic medication.

Authors:  Jonathan Ryan; Ferdia Bolster; Ian Crosbie; Eoin Kavanagh
Journal:  Skeletal Radiol       Date:  2013-01-19       Impact factor: 2.199

Review 8.  Pharmacogenetics and anticoagulant therapy.

Authors:  Brian F Gage; Charles S Eby
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

9.  The Environmental Polymorphisms Registry: a DNA resource to study genetic susceptibility loci.

Authors:  Patricia C Chulada; Heather L Vahdat; Richard R Sharp; Tracy C DeLozier; Paul B Watkins; Susan N Pusek; Perry J Blackshear
Journal:  Hum Genet       Date:  2008-01-10       Impact factor: 4.132

10.  CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry.

Authors:  Carrie M Mosher; Guoying Tai; Allan E Rettie
Journal:  J Pharmacol Exp Ther       Date:  2009-03-03       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.